<DOC>
	<DOCNO>NCT01731327</DOCNO>
	<brief_summary>This study explore drug behavior safety follow single dos tofacitinib modified-release ( MR ) 11 mg MR 22 mg healthy volunteer .</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate The Pharmacokinetics ( PK ) , Safety , And Bioavailability Of A Modified-Release ( MR ) Formulation Of Tofacitinib In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male subject and/or healthy female subject nonchildbearing potential . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ; Clinically significant infection within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>modify release</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>